Moderators: drkazmd65 , The_Q
Search This Board: 
Created: 06/10/2000 10:20:53 AM - Followers: 382 - Board type: Free - Posts Today: 8

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4





Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.CANCER - MULTIKINE

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

    Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1


https://frugalnorwegian.com/cvm  Insight into CVM P3 Trial Results

https://www.cvmresearch.com  Insight into CVM P3 Trial Results & FDA Chances of Approval

PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#40118
CEL-SCI: Pivotal Clinical Trial Results Point To Upside conix 07/14/2021 09:52:06 PM
#41927
Tarius sushifishman 06/29/2022 06:50:40 PM
#41926
shoulda waited, $2s coming tarius729 06/29/2022 06:30:47 PM
#41925
sushifishman Wednesday, June 29, 2022 12:24:31 PM Henkel 06/29/2022 05:04:46 PM
#41924
sushifishman Monday, April 11, 2022 10:14:53 AM Henkel 06/29/2022 04:50:50 PM
#41922
Loaded up and ready for next PUMP Go CVM Cheers sushifishman 06/29/2022 03:36:28 PM
#41921
Almost ready for another SWING! sushifishman 06/29/2022 12:24:31 PM
#41920
I’m ready to buy another swing position in sushifishman 06/29/2022 09:39:52 AM
#41919
tell him soon or "$2s coming" cheers woof tarius729 06/28/2022 11:11:28 PM
#41918
Gavin just called me to ask for my The_Q 06/28/2022 09:03:38 PM
#41917
32.07% daily short volume on Tuesday! Phoenix2020 06/28/2022 08:34:30 PM
#41916
@Cat Zero Mention of a Journal. sushifishman 06/28/2022 05:32:22 PM
#41915
Remind me: Did he say the journal article catinhat 06/28/2022 04:04:38 PM
#41914
sushifishman Monday, June 28, 2021 5:50:07 PM Henkel 06/28/2022 03:42:54 PM
#41913
sushifishman Monday, June 28, 2021 10:35:04 AM Henkel 06/28/2022 03:38:33 PM
#41912
sushifishman $2s coming Henkel 06/28/2022 03:25:40 PM
#41910
Thanks Captain obvious. What would we do w/o thinkingonlygreen 06/28/2022 02:33:06 PM
#41909
1 Yr Anniversary of Trial failing it’s primary sushifishman 06/28/2022 12:44:34 PM
#41908
"daily short volume"s meaningless intra-day order processing volume. Homebrew 06/27/2022 07:32:38 PM
#41907
38.81% daily short volume but PPS up 1.56%! Phoenix2020 06/27/2022 07:29:39 PM
#41906
A 10-day run up from some of our drkazmd65 06/27/2022 04:48:38 PM
#41905
ya, right. Up 40% in 10 days is remittekram 06/27/2022 04:06:18 PM
#41904
Nothing interesting or consistent is going to happen drkazmd65 06/27/2022 01:30:03 PM
#41903
Pre Market--7:01 AM EDT conix 06/27/2022 08:52:39 AM
#41902
Sorry. That’s a quote from Tony on yahoo. sushifishman 06/24/2022 05:51:57 PM
#41901
CVM was dropped out of the Russell. stingman49 06/24/2022 05:44:51 PM
#41900
thanks stingman49 06/24/2022 05:42:57 PM
#41898
Thought it would run again like the last RobotDroid 06/24/2022 02:32:14 PM
#41897
Robert, you bought 5000 shares of a 30 stingman49 06/24/2022 02:21:24 PM
#41896
I picked up 5k KTRA in pre market RobotDroid 06/24/2022 09:30:04 AM
#41895
Shabbat Shalom With CVM being kicked of the Russell sushifishman 06/24/2022 08:51:36 AM
#41894
Nice, Robot! Good luck with the trifecta! Dr. Johnny Fever 06/24/2022 08:43:31 AM
#41893
38.61% daily short volume but PPS up 13.18%! Phoenix2020 06/23/2022 07:17:43 PM
#41892
$415s coming cheers you sound mad tarius729 06/23/2022 06:13:28 PM
#41891
The spike high and somewhat below that show sab63090 06/23/2022 03:53:07 PM
#41889
$4.15 Foxwoods sushifishman 06/23/2022 12:20:55 PM
#41888
I’ll wait till gets down to $415 Foxwoods Man 06/23/2022 12:15:44 PM
#41887
sushifishman Friday, June 10, 2022 10:02:34 AM Henkel 06/23/2022 11:58:09 AM
#41886
Woof! Good thing I sold the stinker in the sushifishman 06/23/2022 11:53:51 AM
#41885
You are funny Wernaaa 06/23/2022 11:42:04 AM
#41884
Easiest stock to swing Will buy back in low $4s Cheers sushifishman 06/23/2022 11:40:20 AM
#41883
A trifecta of brain cancer stocks on the RobotDroid 06/23/2022 11:22:42 AM
#41882
Thanks Guys sushifishman 06/23/2022 11:14:03 AM
#41881
Wow... we haven't seen $5 in a long while! Dr. Johnny Fever 06/23/2022 11:00:25 AM
#41880
He sold. Henkel 06/23/2022 10:51:23 AM
#41877
Sush: Why don't you take a screen shot thinkingonlygreen 06/23/2022 10:15:36 AM
#41876
Go CVM Will sell my 36K shortly Cheers sushifishman 06/23/2022 10:08:03 AM
#41875
32.17% daily short volume but PPS up 8.11%! Phoenix2020 06/22/2022 06:59:49 PM
#41874
Just kinda read his posts and move on...not Foxwoods Man 06/22/2022 05:44:50 PM
#41873
he said he was stopped out last week. stingman49 06/22/2022 05:23:21 PM
#41871
$2s coming tarius729 06/22/2022 04:38:29 PM
Post Subject